← Back to Screener
BridgeBio Pharma, Inc. Common Stock (BBIO)
Price$77.51
Favorite Metrics
Price vs S&P 500 (26W)36.52%
Price vs S&P 500 (4W)4.99%
Market Capitalization$15.03B
All Metrics
Book Value / Share (Quarterly)$0.47
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)86.30%
Cash Flow / Share (Quarterly)$-2.34
Price vs S&P 500 (YTD)-1.06%
Gross Margin (TTM)95.82%
Net Profit Margin (TTM)-144.39%
EPS (TTM)$-3.78
10-Day Avg Trading Volume1.68M
EPS Excl Extra (TTM)$-3.78
Revenue Growth (5Y)127.44%
EPS (Annual)$-3.79
ROI (Annual)-83.58%
Gross Margin (Annual)95.82%
Net Profit Margin (5Y Avg)-1745.26%
Cash / Share (Quarterly)$3.02
Revenue Growth QoQ (YoY)2521.18%
ROA (Last FY)-77.45%
Revenue Growth TTM (YoY)126.26%
EBITD / Share (TTM)$-2.59
Operating Margin (TTM)-108.46%
Cash Flow / Share (Annual)$-2.34
P/B Ratio259.52x
P/B Ratio (Quarterly)150.71x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)34.19x
Net Interest Coverage (TTM)-2.17x
ROA (TTM)-74.43%
EPS Incl Extra (Annual)$-3.79
Current Ratio (Annual)2.77x
Quick Ratio (Quarterly)2.53x
3-Month Avg Trading Volume2.50M
52-Week Price Return122.96%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-7.09
P/S Ratio (Annual)29.93x
Asset Turnover (Annual)0.54x
52-Week High$84.94
Operating Margin (5Y Avg)-1664.55%
EPS Excl Extra (Annual)$-3.79
CapEx CAGR (5Y)4.99%
26-Week Price Return40.51%
Quick Ratio (Annual)2.53x
13-Week Price Return1.12%
Total Debt / Equity (Annual)8.27x
Current Ratio (Quarterly)2.77x
Enterprise Value$17,163.692
Revenue / Share Growth (5Y)106.45%
Asset Turnover (TTM)0.52x
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-145.89%
Cash / Share (Annual)$3.02
3-Month Return Std Dev56.75%
Gross Margin (5Y Avg)91.77%
Net Income / Employee (TTM)$-1
ROE (Last FY)-774.99%
Net Interest Coverage (Annual)-2.17x
EPS Basic Excl Extra (Annual)$-3.79
Receivables Turnover (TTM)6.97x
Total Debt / Equity (Quarterly)8.27x
EPS Incl Extra (TTM)$-3.78
ROI (TTM)-65.34%
P/S Ratio (TTM)29.93x
Pretax Margin (5Y Avg)-1775.49%
Revenue / Share (Annual)$2.62
Tangible BV / Share (Annual)$-8.52
Price vs S&P 500 (52W)93.13%
Year-to-Date Return1.58%
5-Day Price Return2.89%
EPS Normalized (Annual)$-3.79
ROA (5Y Avg)-77.25%
Net Profit Margin (Annual)-144.39%
Month-to-Date Return4.63%
Cash Flow / Share (TTM)$-3.94
EBITD / Share (Annual)$-2.59
Operating Margin (Annual)-108.46%
LT Debt / Equity (Annual)8.22x
ROI (5Y Avg)-78.45%
LT Debt / Equity (Quarterly)8.22x
EPS Basic Excl Extra (TTM)$-3.78
P/B Ratio (Annual)150.71x
Pretax Margin (TTM)-145.89%
Book Value / Share (Annual)$0.47
Price vs S&P 500 (13W)0.43%
Beta1.12x
Revenue / Share (TTM)$2.59
ROE (TTM)-206.74%
52-Week Low$31.77
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.25
4.25
4.28
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BBIOBridgeBio Pharma, Inc. Common Stock | 29.93x | 126.26% | 95.82% | — | $77.51 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
BridgeBio Pharma develops treatments for genetic diseases through a late-stage pipeline of four programs targeting Mendelian disorders, oncology, and gene therapy. Its lead candidate, Attruby (acoramidis), is an orally administered small molecule designed to stabilize transthyretin for the treatment of transthyretin amyloid cardiomyopathy.